Consistent with the requirement for MAPK signaling in KRAS-driven lung cancer, these findings suggest that Kras allelic imbalance may further promote MAPK pathway activity and tumor growth (Blasco et al, 2011; Burgess et al, 2017; Drosten and Barbacid, 2020; Junttila et al, 2010). The gene discussed is KRAS; the disease is neoplasm.